Rapamicina<\/em> \u00e9 um medicamento aprovado pela FDA que j\u00e1 demonstrou prolongar a vida de modelos de camundongos sem progeria. Este novo estudo demonstra que a rapamicina diminui a quantidade da prote\u00edna progerina causadora da doen\u00e7a em 50%, melhora a forma nuclear anormal e estende a vida \u00fatil das c\u00e9lulas de progeria. Este estudo fornece a primeira evid\u00eancia de que a rapamicina pode ser capaz de diminuir H\u00e1 uma tremenda cobertura da m\u00eddia sobre isso! Clique abaixo para links para hist\u00f3rias da m\u00eddia:<\/p>\n Blog de sa\u00fade do Wall Street Journal<\/a><\/strong><\/p>\n Not\u00edcias dos EUA e Relat\u00f3rio Mundial<\/a><\/strong><\/p>\n Revista Ci\u00eancia<\/a><\/strong><\/p>\n Globo de Boston<\/a><\/strong><\/p>\n CNN<\/strong> (link n\u00e3o est\u00e1 mais ativo) A Progeria Research Foundation teve o prazer de fornecer c\u00e9lulas para este projeto da Banco de c\u00e9lulas e tecidos PRF<\/a>, e ajudar a financiar a pesquisa por meio de nosso programa de bolsas<\/a>.<\/p>\n Este novo estudo empolgante demonstra o ritmo not\u00e1vel da pesquisa sobre prog\u00e9ria, ao mesmo tempo em que fornece mais informa\u00e7\u00f5es sobre o processo de envelhecimento que afeta a todos n\u00f3s.<\/p>\n *\u201dRapamicina reverte fen\u00f3tipos celulares e aumenta a elimina\u00e7\u00e3o de prote\u00ednas mutantes em c\u00e9lulas de Hutchinson-Gilford Progeria\u201d [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Researchers at the National Institutes of Health and Massachusetts General Hospital in Boston, MA published a new study today in Science, Translational Medicine that may lead to a new drug treatment for children with Progeria.* Rapamycin is an […]<\/p>","protected":false},"author":1,"featured_media":11636,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" [vc_custom_heading text=\"PRF-funded study Identifies Rapamycin as Possible Treatment for Progeria\" font_container=\"tag:h1|text_align:left\" use_theme_fonts=\"yes\"]<\/p> Researchers at the National Institutes of Health and Massachusetts General Hospital in Boston, MA published a new study today in Science, Translational Medicine<\/em> that may lead to a new drug treatment for children with Progeria.*<\/p> Rapamycin<\/em> is an FDA approved drug that has previously been shown to extend the lives of non-progeria mouse models. This new study demonstrates that rapamycin decreases the amount of the disease-causing protein progerin by 50%, improves the abnormal nuclear shape, and extends the lifespan of progeria cells. This study provides the first evidence that rapamycin may be able to decrease There is tremendous media coverage on this! Click below for links to media stories:<\/p> Wall Street Journal Health Blog<\/a><\/strong><\/p> US News and World Report<\/a><\/strong><\/p> Science Magazine<\/a><\/strong><\/p> Boston Globe<\/a><\/strong><\/p> CNN<\/a> The Progeria Research Foundation was delighted to provide cells for this project from the PRF Cell & Tissue Bank<\/a>, and help fund the research through our grants program<\/a>.<\/p> This exciting new study demonstrates the remarkable pace of progeria research, while providing further insight into the aging process that affects us all.<\/p> *\"Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Cells\"![\"\"](\"https:\/\/web.archive.org\/web\/20170216095136im_\/https:\/\/www.progeriaresearch.org\/assets\/images\/medical_images\/Cao-with-caption.jpg\")
efeitos nocivos da progerina em crian\u00e7as com prog\u00e9ria.<\/p>\n
<\/strong><\/p>\n
Kan Cao, John J. Graziotto, Cecilia D. Blair, Joseph R. Mazzulli, Michael R. Erdos, Dimitri Krainc, Francis S. Collins
29 de junho de 2011 Vol 3 Edi\u00e7\u00e3o 89
Epub antes da impress\u00e3o<\/p>\n<\/div>\nprogerin's damaging effects in children with progeria.<\/p>
<\/strong><\/p>
Kan Cao, John J. Graziotto, Cecilia D. Blair, Joseph R. Mazzulli, Michael R. Erdos, Dimitri Krainc, Francis S. Collins
29 June 2011 Vol 3 Issue 89
Epub ahead of print<\/p><\/div>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-2054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\n